New Russian anti-hep C program provides opportunities for global drugmakers

The Russian Ministry of Health has officially presented a draft federal program to combat mortality from hepatitis C in Russia – a state program, adoption of which has been lobbied for by the patient community in Russia since 2011, reports The Pharma Letter’s local correspondent.

According to Vladimir Chulanov, chief infectious disease specialist of the Russian Ministry of Health, the program will ensure treatment of all patients with hepatitis C who are registered at the dispensary by 2030. Now this includes 700,000 people, only 2%-3% of whom receive regular treatment.

The adoption of the program became part of the list of measures to reduce mortality from several diseases, including from chronic viral hepatitis C, which were prepared in accordance with the earlier order of Russia’s President Vladimir Putin.